Thr449
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr449  -  DBF4 (human)

Site Information
DDIRQNFtQLPLHkN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 23010416

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 )
Relevant cell line - cell type - tissue:
U2OS (bone cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
ATM (human) ( 1 ) , ATR (human) ( 1 )
Kinases, in vitro:
ATM (human) ( 1 ) , ATR (human) ( 1 )

Downstream Regulation
Effects of modification on biological processes:
cell cycle regulation ( 1 )

References 

1

Lee AY, et al. (2012) Dbf4 is direct downstream target of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) protein to regulate intra-S-phase checkpoint. J Biol Chem 287, 2531-43
22123827   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.